Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17463516 | 1.00 | P2RY2 (0.31) | P2RY2P2RY4 | |
| SCHEMBL14928473 | 1.00 | P2RY2 (0.31) | P2RY2P2RY4 | |
| SCHEMBL14946045 | 1.00 | P2RY2 (0.31) | P2RY2P2RY4 | |
| SCHEMBL14928523 | 1.00 | P2RY2 (0.31) | P2RY2P2RY4 | |
| SCHEMBL18118110 | 1.00 | P2RY2 (0.31) | P2RY2P2RY4 | |
| SCHEMBL17463520 | 1.00 | P2RY2 (0.31) | P2RY2P2RY4 | |
| SCHEMBL18118109 | 1.00 | P2RY2 (0.31) | P2RY2P2RY4 | |
| SCHEMBL15257874 | 0.90 | — | — | |
| SCHEMBL15249820 | 0.90 | — | — | |
| SCHEMBL14583693 | 0.84 | ADORA2A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9504734-B2 | Modified polynucleotides for the production of nuclear proteins | MODERNATX, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160114011-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2016-04-28 | — | — | US | disclosed |
| US-9283287-B2 | Modified polynucleotides for the production of nuclear proteins | MODERNA THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9220792-B2 | Modified polynucleotides encoding aquaporin-5 | MODERNA THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9216205-B2 | Modified polynucleotides encoding granulysin | MODERNA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9149506-B2 | Modified polynucleotides encoding septin-4 | MODERNA THERAPEUTICS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150246139-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2015-09-03 | — | — | US | disclosed |
| US-20140255468-A1 | MODIFIED POLYNUCLEOTIDES ENCODING PROGRAMMED CELL DEATH 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140179771-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING DOLICHYL-PHOSPHATE (UDP-N-ACETYLGLUCOSAMINE) N-ACETYLGLUCOSAMINEPHOSPHOTRANSFERASE 1 (GLCNAC-1-P TRANSFERASE) PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | MODERNA THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140105964-A1 | MODIFIED POLYNUCLEOTIDES ENCODING AQUAPORIN-5 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130244279-A1 | FORMULATION AND DELIVERY OF PLGA MICROSPHERES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130236974-A1 | METHOD FOR INCREASING THE PRODUCTION OF A PROTEIN OF INTEREST | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237593-A1 | MULTI-SITE ADMINISTRATION | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | SEPTIN7, SEPTIN9, SEPTIN8 | P2RY2 4062/4885P2RY4 2455/4885 |
| US-20130237593-A1 | MULTI-SITE ADMINISTRATION | PHAX, IGF2BP1, NSUN2 | P2RY2 3992/4885P2RY4 4300/4885 |
| US-20150246139-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | P2RY2 3286/4885P2RY4 3464/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | P2RY2 558/4885P2RY4 427/4885 |
| US-20140105964-A1 | MODIFIED POLYNUCLEOTIDES ENCODING AQUAPORIN-5 | AQP1, AQP3, AQP4 | P2RY2 999/4885P2RY4 1210/4885 |
| US-20130236974-A1 | METHOD FOR INCREASING THE PRODUCTION OF A PROTEIN OF INTEREST | IGF2BP1, PHAX, IGF2BP2 | P2RY2 4132/4885P2RY4 4426/4885 |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | P2RY2 3344/4885P2RY4 3802/4885 |
| US-20160114011-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | P2RY2 3286/4885P2RY4 3464/4885 |
| US-20140179771-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING DOLICHYL-PHOSPHATE (UDP-N-ACETYLGLUCOSAMINE) N-ACETYLGLUCOSAMINEPHOSPHOTRANSFERASE 1 (GLCNAC-1-P TRANSFERASE) PROTEIN DEFICIENCY | POLRMT, POLN, GALNT1 | P2RY2 2757/4885P2RY4 2698/4885 |
| US-20140255468-A1 | MODIFIED POLYNUCLEOTIDES ENCODING PROGRAMMED CELL DEATH 1 | MSH2, POLRMT, PDCD1 | P2RY2 3134/4885P2RY4 3243/4885 |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | P2RY2 3235/4885P2RY4 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.